Marco Advisor generates diagnostic, prognostic and therapeutic recommendations for Bladder Cancer directly from clinical records in the hospital information system. The system integrates biomarkers such as FGFR2/3 and PD-L1 with EAU/NCCN guidelines to deliver structured, auditable recommendations to the treating team.
Some answers to questions we often receive
Marco Advisor connects to existing HIS/EMR systems via standard APIs (HL7 FHIR), requiring no data migration. It reads structured fields from Bladder Cancer patient records and returns recommendations directly in the usual clinical interface, minimizing workflow disruption.
Yes. Marco Advisor's evidence engine updates continuously with EAU/NCCN guidelines and relevant clinical trials for Bladder Cancer. Recommendation changes are reflected automatically without manual updates by the clinical team.
Yes. Marco Advisor automatically cross-references clinical records with current Bladder Cancer guidelines and identifies opportunities such as indicated but unrequested molecular testing (FGFR2/3 and PD-L1), therapy line changes per progression criteria, or available clinical trial eligibility, generating alerts to the treating team.
Marco Advisor generates three recommendation categories: diagnostic (alerts on pending testing such as FGFR2/3 and PD-L1), prognostic (risk stratification by stage and molecular factors) and therapeutic (treatment recommendations aligned with EAU/NCCN guidelines, interaction alerts and contraindications).
Marco Advisor processes data within the hospital environment (on-premise or private cloud), without transmitting identifiable information to external servers. The system complies with health data protection regulations (HIPAA, GDPR and local norms) with full audit trails of access and data use.
Marco Advisor implementation is modular: it can start with the oncology service or Bladder Cancer tumor board and scale gradually. The Marco team supports implementation with HIS connector configuration, local clinical validation and team training, with continuous post-implementation support.
BCG protocols in NMIBC and escalation criteria in advanced bladder cancer are not uniformly applied because there is no systematic alert in the chart.